 After completion of radiotherapy to all disease sites, patients will be followed every 3-4 months with PSA testing until the development of castrate resistant prostate cancer. At the same time points, late toxicity and quality of life will be collected for a minimum of 2 years. Computed tomography CT of the chestabdopelvis - magnetic resonance imaging MRI of previously irradiated body sites and bone scan will be performed whenever the PSA reaches 10 ngmL prior to re-starting androgen deprivation therapy during intermittent hormone therapy approach, or at a minimum frequency of once per year. 